Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.

× No keyword cloud information.

6 in total

Review 1. Iron-chelating therapy with the new oral agent ICL670 (Exjade).

Authors: M D Cappellini
Journal: Best Pract Res Clin Haematol Date: 2005-06 Impact factor: 3.020

2. Deferiprone iron chelation as a novel therapy for experimental mucormycosis.

Authors: Ashraf S Ibrahim; John E Edwards; Yue Fu; Brad Spellberg
Journal: J Antimicrob Chemother Date: 2006-08-23 Impact factor: 5.790

3. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice.

Authors: Brad Spellberg; Yue Fu; John E Edwards; Ashraf S Ibrahim
Journal: Antimicrob Agents Chemother Date: 2005-02 Impact factor: 5.191

Review 4. Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors: Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal: Clin Microbiol Rev Date: 2005-07 Impact factor: 26.132

5. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors: J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal: J Clin Invest Date: 1993-05 Impact factor: 14.808

6. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.

Authors: J R Boelaert; J Van Cutsem; M de Locht; Y J Schneider; R R Crichton
Journal: Kidney Int Date: 1994-03 Impact factor: 10.612

6 in total

29 in total

1. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

Authors: Brad Spellberg; Ashraf S Ibrahim; Peter V Chin-Hong; Dimitrios P Kontoyiannis; Michele I Morris; John R Perfect; David Fredricks; Eric P Brass
Journal: J Antimicrob Chemother Date: 2011-09-20 Impact factor: 5.790

2. Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans.

Authors: Sonia Brena; Jonathan Cabezas-Olcoz; María D Moragues; Iñigo Fernández de Larrinoa; Angel Domínguez; Guillermo Quindós; José Pontón
Journal: Antimicrob Agents Chemother Date: 2011-04-25 Impact factor: 5.191

3. Combination therapy for mucormycosis: why, what, and how?

Authors: Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal: Clin Infect Dis Date: 2012-02 Impact factor: 9.079

4. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis.

Authors: Alexis Soummer; Armelle Mathonnet; Olivier Scatton; Pierre Philippe Massault; André Paugam; Virginie Lemiale; Jean Paul Mira; Eric Dannaoui; Alain Cariou; Olivier Lortholary
Journal: Antimicrob Agents Chemother Date: 2008-01-22 Impact factor: 5.191

5. The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis.

Authors: A Busca; G Limerutti; F Locatelli; A Barbui; F G De Rosa; M Falda
Journal: Infection Date: 2011-07-07 Impact factor: 3.553

Review 6. Targeting iron assimilation to develop new antibacterials.

Authors: Timothy L Foley; Anton Simeonov
Journal: Expert Opin Drug Discov Date: 2012-07-19 Impact factor: 6.098

7. Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin.

Authors: Paris Laskaris; Ahmad Atrouni; José Antonio Calera; Christophe d'Enfert; Hélène Munier-Lehmann; Jean-Marc Cavaillon; Jean-Paul Latgé; Oumaïma Ibrahim-Granet
Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191

Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.